Inorganic phosphate as a novel signaling molecule with antiproliferative action in MDA-MB-231 breast cancer cells

BioResearch Open Access

Volumn 2, Issue 1, 2013, Pages 47-54

  Spina, Annamaria ^a   Sapio, Luigi ^a   Esposito, Antonietta ^a   Di Maiolo, Francesca ^a   Sorvillo, Luca ^a   Naviglio, Silvio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

ERK1 2; growth inhibition; inorganic phosphate; MDA MB 231 cells; STAT3

Indexed keywords

CYCLIN A; CYCLIN E; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATE; PROTEIN P21; PROTEIN P27; STAT3 PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84897654822     PISSN: None     EISSN: 21647860     Source Type: Journal    
DOI: 10.1089/biores.2012.0266     Document Type: Article

References (53)

1. Yoshiko Y, Candeliere GA, Maeda N, Aubin JE. Osteoblast autonomous Pi regulation via Pit1 plays a role in bone mineralization. Mol Cell Biol. 2007;27:4465-4474.
2. Takeda E, Taketani Y, Sawada N, et al. The regulation and function of phosphate in the human body. Biofactors. 2004; 21:345-355.
3. Prié D, Beck L, Urena P, Friedlander G. Recent findings in phosphate homeostasis. Curr Opin Nephrol Hypertens. 2005; 14:318-324.
4. Harum P. Phosphorus additives. A problem for ESRD patients and the public. Nephrol News Issues. 2012;26:16-17.
5. Kemi VE, Rita HJ, Ka?rkka? inen MU, et al. Habitual high phosphorus intakes and foods with phosphate additives negatively affect serum parathyroid hormone concentration: a cross-sectional study on healthy premenopausal women. Public Health Nutr. 2009;12:1885-1892.
6. Jun W, Lin L, Yurong C, Juming Y. Recent advances of calcium phosphate nanoparticles for controlled drug delivery. Mini Rev Med Chem. 2012 Jun 13 [Epub ahead of print]; PMID: 22697516.
7. Kim YS, Milner JA. Bioactive food components and cancerspecific metabonomic profiles. J Biomed Biotechnol. 2011: 721213.
8. Welch AA, Fransen H, Jenab M, et al. Variation in intakes of calcium, phosphorus, magnesium, iron and potassium in 10 countries in the European Prospective Investigation into Cancer and Nutrition study. Eur J Clin Nutr. 2009;63(Suppl 4):S101-121.
9. Khoshniat S, Bourgine A, Julien M, et al. The emergence of phosphate as a specific signaling molecule in bone and other cell types in mammals. Cell Mol Life Sci. 2011;68:205-218.
10. Naviglio S, Spina A, Chiosi E, et al. Inorganic phosphate inhibits growth of human osteosarcoma U2OS cells via adenylate cyclase/cAMP pathway. J Cell Biochem. 2006;98: 1584-1596.
11. Naviglio S, Di Gesto D, Borrelli V, et al. Novel molecular mechanisms by inorganic phosphate in osteosarcoma U2OS cells. Front Biosci. 2011;E3:1249-1258.
12. Spina A, Sorvillo L, Di Maiolo F, et al. Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53-dependent pathway. J Cell Physiol. 2013;228:198-206.
13. Camalier CE, Young MR, Bobe G, et al. Elevated phosphate activates N-ras and promotes cell transformation and skin tumorigenesis. Cancer Prev Res. 2010;3:359-370.
14. Naviglio S, Di Gesto D, Romano M, et al. Leptin enhances growth inhibition by cAMP elevating agents through apoptosis of MDA-MB-231 breast cancer cells. Cancer Biol Ther. 2009;8:1183-1190.
15. Naviglio S, Di Gesto D, Illiano F, et al. Leptin potentiates antiproliferative action of cAMP elevation via protein kinase A down-regulation in breast cancer cells. J Cell Physiol. 2010;225:801-809.
16. Chiosi E, Spina A, Sorrentino A, et al. Change in TNF-alpha receptor expression is a relevant event in doxorubicininduced H9c2 cardiomyocyte cell death. J Interferon Cytokine Res. 2007;27:589-597.
17. Naviglio S, Spina A, Marra M, et al. Adenylate cyclase/ cAMP pathway downmodulation counteracts apoptosis induced by IFN-alpha in human epidermoid cancer cells. J Interferon Cytokine Res. 2007;27:129-136.
18. Radestock Y, Hoang-Vu C, Hombach-Klonisch S. Relaxin reduces xenograft tumour growth of human MDA-MB-231 breast cancer cells. Breast Cancer Res. 2008;10:R71.
19. Du J, Sun C, Hu Z, et al. Lysophosphatidic acid induces MDA-MB-231 breast cancer cells migration through activation of PI3K/PAK1/ERK signaling. PLoS One. 2010;30; 5:e15940.
20. Liu B, Fan Z, Edgerton SM, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009;8:2031-2040.
21. Borriello A, Bencivenga D, Criscuolo M, et al. Targeting p27Kip1 protein: its relevance in the therapy of human cancer. Expert Opin Ther Targets. 2011;15:677-693.
22. Kim SH, Nagalingam A, Saxena NK, et al. Benzyl isothiocyanate inhibits oncogenic actions of leptin in human breast cancer cells by suppressing activation of signal transducer and activator of transcription 3. Carcinogenesis. 2010;32:359-367.
23. Yang LH, Ho YJ, Lin JF, et al. Butein inhibits the proliferation of breast cancer cells through generation of reactive oxygen species and modulation of ERK and p38 activities. Mol Med Rep. 2012;6:1126-1132.
24. Rakha EA, Chan S. Metastatic triple-negative breast cancer. Clin Oncol. 2011;23:587-600.
25. Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125: 627-636.
26. Raina K, Agarwal R. Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms. Acta Pharmacol Sin. 2007;28:1466-1475.
27. Szekeres T, Saiko P, Fritzer-Szekeres M, et al. Chemopreventive effects of resveratrol and resveratrol derivatives. Ann NY Acad Sci. 2011;1215:89-95.
28. Manu KA, Shanmugam MK, Rajendran P, et al. Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4. Mol Cancer. 2011;10:107.
29. Siebert AE, Sanchez AL, Dinda S, Moudgil VK. Effects of estrogen metabolite 2-methoxyestradiol on tumor suppressor protein p53 and proliferation of breast cancer cells. Syst Biol Reprod Med. 2011;57:279-287.
30. Chen JT, Fong YC, Li TM, et al. DDTD, an isoflavone derivative, induces cell apoptosis through the reactive oxygen species/apoptosis signal-regulating kinase 1 pathway in human osteosarcoma cells. Eur J Pharmacol. 2008;597:19-26.
31. Go VL, Wong DA, Wang Y, et al. Diet and cancer prevention: evidence-based medicine to genomic medicine. J Nutr. 2004; 134:3513-3516S.
32. Su LJ. 2012. Diet, epigenetics, and cancer. Methods Mol Biol. 2012;863:377-393.
33. Ichikawa S, Austin AM, Gray AK, et al. Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosis. Endocrinology. 2011;152:4504-4513.
34. Jin H, Xu CX, Lim HT, et al. High dietary inorganic phosphate increases lung tumorigenesis and alters Akt signaling. Am J Respir Crit Care Med. 2009;179:59-68.
35. Xu CX, Jin H, Lim HT, et al. Low dietary inorganic phosphate stimulates lung tumorigenesis through altering protein translation and cell cycle in K-ras(LA1) mice. Nutr Cancer. 2010;62:525-532.
36. Pal D, Banerjee S, Ghosh AK. Dietary-induced cancer prevention: An expanding research arena of emerging diet related to healthcare system. J Adv Pharm Technol Res. 2012;3:16-24.
37. Beck GR Jr. Inorganic phosphate as a signaling molecule in osteoblast differentiation. J Cell Biochem. 2003;90:234-243.
38. Kemi VE, Karkkainen MU, Lamberg-Allardt CJ. High phosphorus intakes acutely and negatively affect Ca and bone metabolism in a dose-dependent manner in healthy young females. Br J Nutr. 2006;96:545-552.
39. Jin H, Hwang SK, Yu K, et al. A high inorganic phosphate diet perturbs brain growth, alters Akt-ERK signaling, and results in changes in cap-dependent translation. Toxicol Sci. 2006;90:221-229.
40. Jin H, Chang SH, Xu CX, et al. High dietary inorganic phosphate affects lung through altering protein translation, cell cycle, and angiogenesis in developing mice. Toxicol Sci. 2007;100:215-223.
41. Xu CX, Jin H, Lim HT, et al. High dietary inorganic phosphate enhances cap-dependent protein translation, cellcycle progression, and angiogenesis in the livers of young mice. Am J Physiol Gastrointest Liver Physiol. 2008;295: G654-G663.
42. Bourgine A, Beck L, Khoshniat S, et al. Inorganic phosphate stimulates apoptosis in murine MO6-G3 odontoblast-like cells. Arch Oral Biol. 2011;56:977-983.
43. Cox RF, Jenkinson A, Pohl K, et al. Osteomimicry of mammary adenocarcinoma cells in vitro; increased expression of bone matrix proteins and proliferation within a 3D collagen environment. PLoS One. 2012;7:e41679.
44. Cox RF, Hernandez-Santana A, Ramdass S, et al. Microcalcifications in breast cancer: novel insights into the molecular mechanism and functional consequence of mammary mineralisation. Br J Cancer. 2012;106:525-537.
45. Santen RJ, Song RX, McPherson R, et al. The role of mitogenactivated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol. 2002;80:239-256.
46. Chiaradonna F, Balestrieri C, Gaglio D, Vanoni M. RAS and PKA pathways in cancer: new insight from transcriptional analysis. Front Biosci. 2008;13:5257-5278.
47. Mannello F, Papa S. HER2 and proliferation of woundinduced breast carcinoma. Lancet. 2003;362:1503-1504.
48. Alvarez RH, Valero V, Hortobagyi GN. Emerging targeted therapies for breast cancer. J Clin Oncol. 2010;28:3366-3379.
49. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:103-119.
50. Jing N, Tweardy DJ. Targeting Stat3 in cancer therapy. Anticancer Drugs. 2005;16:601-607.
51. Germain D, Frank DA. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res. 2007;13: 5665-5669.
52. Johnston PA, Grandis Jr. STAT3 signaling: anticancer strategies and challenges. Mol Interv. 2011;11:18-26.
53. Reddy KB. Triple-negative breast cancers: an updated review on treatment options. Curr Oncol. 2011;18:173-179.